Epigenetics and cancer

Research output: Contribution to journalReview articlepeer-review

Abstract

The activation of oncogenes and/or the deactivation of tumor suppression genes involve uncontrolled cell growth which leads to the development of cancer. Downregulation of cell adhesion receptors necessary for tissue-specific, cell-cell attachment, as well as upregulation of receptors that enhance cell motility, is required for metastasis. These characteristics can be modified by epigenetic changes including histone modifications, DNA methylation, and DNA hydroxymethylation. Signaling pathways that regulate apoptosis and autophagy, as well as microRNA, include targets for these epigenetic changes. Predisposed normal cells change to cancer progenitor cells that, after growing, experience an epithelial-mesenchymal transition. Epigenetic medication seems to enhance the action of traditional medicine, usually by demethylating and reexpressing tumor suppressor genes to inhibit tumorigenesis. Adopting epigenetic alteration as a brand new hallmark of cancer could be a logical and necessary step that may additionally encourage the event of novel epigenetic biomarkers and therapeutics.
Original languageEnglish
JournalDrug Invention Today
Publication statusPublished - 1 Feb 2019

Fingerprint

Dive into the research topics of 'Epigenetics and cancer'. Together they form a unique fingerprint.

Cite this